Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report

In conclusion, the combination of tislelizumab and anlotinib may offer a viable therapeutic option for recurrent metastatic BRCA2-mutated PDAC.PMID:38515651 | PMC:PMC10952340 | DOI:10.3892/etm.2024.12466

Source: Experimental and Therapeutic Medicine - March 22, 2024 Category: General Medicine Authors: Sujuan Peng Hongxiang Huang Xie Zhu Jinhong Chen Xinjing Ding Fen Wang Li Chen Zhihui Lu Source Type: research